Topic: chronic kidney disease
Shares in FibroGen plummeted as the wording of its number-free statement raised concerns about the safety of the kidney disease drug.
AstraZeneca tapped BenevolentAI to help bring artificial intelligence and machine learning to its drug discovery projects aimed at CKD and IPF.
The latest failure raised significant doubts about the future of vonapanitase, wiping 85% off Proteon’s stock price.
Though the Japanese data aren’t a perfect predictor for vadadustat’s global registrational studies, Piper Jaffray analysts called them “a nice proxy."
In rodent studies, exon skipping corrected a genetic error that's responsible for kidney disease linked to Joubert syndrome.
The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.
FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO.
Tvardi Therapeutics will finish a phase 1 trial of its lead asset, an oral STAT3 inhibitor, in solid tumors.
The combined company will own potentially complementary kidney disease drugs and a sales force to promote them.
Proceeds from the planned IPO will set Tricida up to file for FDA approval of TRC101 and start building up an 80- to 100-person sales team.